Altimmune, Inc.
ALT
Jodie situation report
Altimmune, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 29 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- ALT's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ALT's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ALT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
HTGCHercules Capital, Inc.lenderMay 13, 2026 ▾
“Sources of Liquidity Loan Financing On May 13, 2025 (“Closing Date”), we entered into a Loan and Security Agreement (“Loan Agreement”) with Hercules Capital, Inc.”
Depended on by
PTGXProtagonist Therapeutics, Inc.partnerFeb 25, 2026 ▾
“Other emerging approaches include dual GLP-1/glucagon receptor agonists, such as survodutide (Boehringer Ingelheim) and pemvidutide (Altimmune).”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ALT is currently a Follower in the organic co-movement group Nuclear and Rare Materials. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ALT; it is not active in the latest market snapshot.